Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 6, 2011, Pages 3002-3004

  Bulik, Catharine C ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEMASE; DORIPENEM; ERTAPENEM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CHEMOSTAT; CONTROLLED STUDY; DRUG EFFICACY; ENZYME SYNTHESIS; FEMALE; IN VITRO STUDY; IN VIVO STUDY; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; THIGH;

ANIMALS; BACTERIAL PROTEINS; BETA-LACTAMASES; CARBAPENEMS; DRUG THERAPY, COMBINATION; FEMALE; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICE; MICE, INBRED ICR;

EID: 79956313039     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01420-10     Document Type: Article

References (12)

1. Anderson, K. F., et al. 2007. Evaluation of methods to identify the Klebsiella pneumoniae carbapenemase in Enterobacteriaceae. J. Clin. Microbiol. 45: 2723-2725. (Pubitemid 47295515)
2. Bulik, C. C., and D. P. Nicolau. 2010. In vivo efficacy of human simulated prolonged infusion doripenem against carbapenemase-producing Klebsiella pneumoniae. Antimicrob. Agents Chemother. 54:4112-4115.
3. Bulik, C. C., et al. 2010. Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 54:804-810.
4. Castanheira, M., H. S. Sader, L. M. Deshpande, T. R. Fritsche, and R. N. Jones. 2008. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-β- lactamase-producing Enterobacteriaceae: report from the SENTRY antimicrobial surveillance program. Antimicrob. Agents Chemother. 52:570-573.
5. Clinical and Laboratory Standards Institute. 2008. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 8th ed. CLSI publication M07-A8. Clinical and Laboratory Standard Institute, Wayne, PA.
6. Crandon, J. L., C. C. Bulik, and D. P. Nicolau. 2009. In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 53:4352-4356.
7. DeRyke, C. A., M. A. Banevicius, H. W. Fan, and D. P. Nicolau. 2007. Bactericidal activities of meropenem and ertapenem against extended-spectrum- beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model. Antimicrob. Agents Chemother. 51:1481-1486.
8. Holmberg, S. D., S. L. Solomon, and P. A. Blake. 1987. Health and economic impacts of antimicrobial resistance. Rev. Infect. Dis. 9:1065-1078.
9. Hussein, K., et al. 2009. Carbapenem resistance among Klebsiella pneumoniae isolates: risk factors, molecular characteristics, and susceptibility patterns. Infect. Control Hosp. Epidemiol. 30:666-671.
10. Kontopoulou, K., et al. 2010. Hospital outbreak caused by Klebsiella pneumoniae producing KPC-2 β-lactamase resistant to colistin. J. Hosp. Infect. 76:70-73.
11. Rhomberg, P. R., L. M. Deshpande, J. T. Kirby, and R. N. Jones. 2007. Activity of meropenem as serine carbapenemases evolve in US medical centers: monitoring report from the MYSTIC program (2006). Diagn. Microbiol. Infect. Dis. 59:425-432.
12. Tóth, Á., et al. 2010. Emergence of a colistin-resistant KPC-2-producing Klebsiella pneumoniae ST258 clone in Hungary. Eur. J. Clin. Microbiol. Infect. Dis. 29:765-769.